Neonatal Respiratory Distress Syndrome Treatment Market is gaining major traction as Windtree Therapeutics, Inc. received the U.S. FDA approval a Phase II clinical trial studying its KL4 surfactant drug in COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS) patients

The symptoms of neonatal respiratory distress syndrome are very similar to those associated with pneumonia and bronchitis, although it can occur in a child less than a year of age. They include excessive coughing, excessive crying, and wheezing of the lungs. As far as the geographical footprint is considered, developed economies such as the U.S. have gained significant traction in the neonatal respiratory distress syndrome treatment market. This is typically due to the fact that there is a high patient pool of RDS and the presence of robust healthcare infrastructure. On the contrary, Europe is gradually exhibiting promising signs in this market due to content R&D activities of pharmaceutical companies in the region.

The demand for respiratory distress syndrome treatment has gone up over the years. This is typically due to the fact that growing cases of rare diseases such as acute respiratory distress syndrome (ARDS). As per the National Organization for Rare Disorders (NORD), ARDS effect 16 individuals per 100,000 people aged 15 to 19 years to 306 individuals per 100,000 people aged between 75 and 84 years. Such a high incidence of these rare diseases has necessitated adequate treatment options. Thus, these factors can stimulate growth of the neonatal respiratory distress syndrome treatment market.

Treatment includes fluid therapy, antibiotics, and a regimen of anti-inflammatory medication, in order to reduce swelling. If the disorder has been diagnosed in an infant less than six months of age, doctors may recommend oxygen therapy. However, there are some adverse effects of existing treatment options, which could a major challenging factor. For instance, surfactant therapy has short-term risks in patients such as bradycardia, hypoxemia during installation, and more. Thus, such factors could potentially limit growth of the neonatal respiratory distress syndrome treatment market.

Treatment options for neonatal respiratory issues vary from child to child depending on the severity of the disorder. Medications and surgeries may be recommended by a doctor to help improve the health of the lungs of the infant. Since there is high prevalence of RDS, many healthcare and biopharmaceutical companies are focused on continuous research and development activities to come up with effective medications and treatment. These activities include product launch, collaborative research, etc. Recently, in April 2019, InnAccel launched SAANS, a neonatal CAPA system for infants with respiratory distress syndrome. Hence, such factors can augment growth of the neonatal respiratory distress syndrome treatment market.

Recently, in September 2020, Windtree Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) application for a Phase II clinical trial studying its KL4 surfactant drug in COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS) patients.